Tag
The ESC HF III Registry found substantial mortality and rehospitalization across heart failure phenotypes. Risk was highest after acute hospitalization and generally worse with reduced ejection fraction, but HFmrEF and HFpEF also carried si
A qualitative study in heart failure shows that medication adherence is shaped by regimen complexity, diuretic burden, psychosocial stressors, cost, and care coordination rather than motivation alone.
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrenti
A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongl
New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
In Medicare beneficiaries, ATTR-CM was diagnosed a median 494 days after heart failure and 840 days after loop diuretic initiation, with delays more common in women and patients with several common comorbidities.
The REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, w
Higher CKM syndrome stages correlate with adverse cardiac remodeling and increased heart failure risk in older adults, as shown in the ARIC Study.
The PURE study reveals significant global disparities in heart failure incidence and mortality, with hypertension as the leading modifiable risk factor, highlighting the need for targeted prevention and treatment strategies.
A study finds bradykinin modestly contributes to blood pressure reduction with sacubitril/valsartan in chronic heart failure, highlighting ANP’s role in initial effects and bradykinin’s influence during chronic therapy.
A randomized trial shows left bundle branch pacing significantly reduces the risk of pacing-induced cardiomyopathy and improves cardiac function compared to right ventricular pacing in high-risk patients.
A study reveals that RV-PA coupling, measured by TAPSE/sPAP ratio, significantly predicts outcomes in HFrEF patients during GDMT up-titration, highlighting its potential as a treatment target.
PhysioSync-HF trial reveals CSP is inferior to BiVP for HFrEF patients with LBBB, challenging its role as a first-line resynchronization therapy despite cost benefits.
The HeartSync-LBBP trial reveals left bundle-branch pacing reduces the composite of death or heart failure hospitalization by 74% compared to biventricular pacing, with significantly higher super-response rates in patients with reduced ejec
A prospective case-control study demonstrates that myocardial fibroblast activation persists in heart failure patients and follows distinct spatial patterns depending on etiology. Using [68Ga]FAPI-46 PET/MRI, researchers found that higher b
A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over
A canine study reveals left bundle branch pacing achieves equivalent QRS narrowing and ejection fraction improvement as biventricular pacing, yet demonstrates superior recovery of cardiac mechanics, calcium handling, and energy metabolism a
A groundbreaking mass spectrometry study analyzing 486 heart failure patients and 98 controls identified over 21,000 unique peptides, revealing 1,924 differentially expressed peptides. The research highlights angiotensin-related peptides, n
A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifia
This review synthesizes recent evidence identifying MR-proADM as a premier prognostic biomarker in ATTR-CM, demonstrating its ability to outperform traditional natriuretic peptides and enhance existing clinical staging systems.
